InvestorsHub Logo
Followers 8
Posts 6947
Boards Moderated 0
Alias Born 07/31/2006

Re: AxiomOne post# 6251

Thursday, 01/31/2008 5:11:30 AM

Thursday, January 31, 2008 5:11:30 AM

Post# of 14825
To clear it up, Axiom I said that Calypte had no FDA approved diagnostic tests in US, and they don't! They had FDA approved urine lab tests, but gave those away.

They do have "customers" of the CDC BED incidence test which doesn't diagnose HIV but rather measures time of infection in patients that already have HIV. This is a blood test and would have no use for oral samples.

Once the oral samples are collected, whose diagnostic test will the lab be using to diagnose HIV in US? HMM Orasure has the only FDA approved test.

So to stretch the PR and make the logical assumption lets see how this will work.

Due to inquiries in US by people who have bought Calypte's BED incidence test (their only US customers), Calypte has developed an oral collection device to send oral fluid to labs to be tested (by Orasure in US?).

Come on axiom does this make any sense to you?

and on international basis, the cost of shipping oral or blood samples plus lab costs to analyze not to mention the delay in getting results completely rules out lab testing where much less expensive rapid tests are available (which is pretty much everywhere).

so unless Orasure is buying these collection devices or Calypte or CDC is ready to announce an FDA approved oral lab test(without ever giving notice that one has been submitted for FDA approval), one can hardly imagine who would buy these devices.

Can you think of who the logical "customer" for those tests may be axiom?





.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.